O19-4 Outcomes in Japanese patients with TMB-high and non-TMB-high solid tumors treated with pembrolizumab: KEYNOTE-158

Shunji Takahashi,Nobumasa Mizuno,Kosei Hasegawa,Koji Matsumoto,Shirong Han,Tsutomu Takatsuki, Jiulun Fan,Kazuhiko Nakagawa

Annals of Oncology（2022）

引用 0|浏览0

暂无评分

摘要

Tissue tumor mutational burden (tTMB) was correlated with response to pembrolizumab (pembro) monotherapy in the global phase 2 KEYNOTE-158 study (NCT02628067). We report an analysis of the relationship between the response to pembro and tTMB in patients with advanced solid tumors in the KEYNOTE-158 study enrolled in Japan.

查看译文

关键词

pembrolizumab,japanese patients,non-tmb-high

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要